Osman Nermin A, Anwar Mohammed Moustapha, Singh Bivek, Gupta Girish K, Rabie Amgad M
Biomedical Informatics and Medical Statistics Department, Medical Research Institute, Alexandria University, Alexandria, Egypt.
Department of Biotechnology, Institute of Graduate Studies and Research (IGSR), Alexandria University, Alexandria, Egypt.
J Egypt Public Health Assoc. 2023 Mar 2;98(1):4. doi: 10.1186/s42506-022-00125-1.
Coronavirus disease 2019 (COVID-19)-associated mucormycosis (CAM) is responsible for a high mortality rate due to its unique and severe host-pathogen interactions. Critically ill or immunocompromised COVID-19 patients are more prone to suffer from aggressive mycoses. Probable victims include those with uncontrolled diabetes mellitus (DM), metabolic acidosis, prolonged neutropenia, increased ferritin levels, hypoxia, and prolonged hospitalization with/without mechanical ventilators and corticosteroids administration. The current review aims to outline the journey of patients with CAM as well as the advantages and disadvantages of the currently available diagnostic techniques. It also discussed the current status of treatment options and caveats in the management of mucormycosis. Multidisciplinary team, early diagnosis, controlling the predisposing condition(s), complete surgical debridement, effective antifungal therapies (e.g., amphotericin B, isavuconazole, and posaconazole), and implementing antifungal stewardship programs are imperative in CAM cases.
2019冠状病毒病（COVID-19）相关毛霉菌病（CAM）因其独特且严重的宿主-病原体相互作用而导致高死亡率。危重症或免疫功能低下的COVID-19患者更容易发生侵袭性真菌病。可能的受害者包括未控制的糖尿病（DM）、代谢性酸中毒、长期中性粒细胞减少、铁蛋白水平升高、缺氧以及接受/未接受机械通气和皮质类固醇治疗的长期住院患者。本综述旨在概述CAM患者的病程以及当前可用诊断技术的优缺点。它还讨论了毛霉菌病治疗选择的现状和管理中的注意事项。在CAM病例中，多学科团队、早期诊断、控制诱发因素、彻底手术清创、有效的抗真菌治疗（如两性霉素B、艾沙康唑和泊沙康唑）以及实施抗真菌管理计划至关重要。
